canertinib dihydrochloride has been researched along with nvp-ast487 in 1 studies
| Studies (canertinib dihydrochloride) | Trials (canertinib dihydrochloride) | Recent Studies (post-2010) (canertinib dihydrochloride) | Studies (nvp-ast487) | Trials (nvp-ast487) | Recent Studies (post-2010) (nvp-ast487) |
|---|---|---|---|---|---|
| 31 | 13 | 6 | 17 | 0 | 14 |
| Protein | Taxonomy | canertinib dihydrochloride (IC50) | nvp-ast487 (IC50) |
|---|---|---|---|
| Tyrosine-protein kinase ABL1 | Homo sapiens (human) | 0.58 | |
| Breakpoint cluster region protein | Homo sapiens (human) | 0.58 | |
| Receptor-type tyrosine-protein kinase FLT3 | Homo sapiens (human) | 0.005 | |
| Cyclin-dependent kinase-like 3 | Homo sapiens (human) | 0.0071 | |
| MAP kinase-interacting serine/threonine-protein kinase 1 | Homo sapiens (human) | 1.76 | |
| MAP kinase-interacting serine/threonine-protein kinase 2 | Homo sapiens (human) | 0.02 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Russu, WA; Shallal, HM | 1 |
1 other study(ies) available for canertinib dihydrochloride and nvp-ast487
| Article | Year |
|---|---|
Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Molecular Structure; Piperazines; Protein Kinase Inhibitors; Protein Kinases; Pyrimidines; Stereoisomerism; Structure-Activity Relationship | 2011 |